恩度隔日给药联合化疗一线治疗晚期消化道癌临床观察

The clinical observation of endostatin administration every other day combined with first-line chemotherapy in the treatment of advanced gastrointestinal cancer

目的评价恩度隔日给药联合化疗一线治疗晚期消化道癌的疗效及毒副反应。方法 21例晚期消化道肿瘤患者,应用恩度7.5 mg/m2（隔日一次）、奥沙利铂85 mg/m2d1、亚叶酸钙200 mg/m2 IV d1、2,5-FU 400 mg/m2Ⅳd1、2,5-FU 2.4 g/m2CIV 46 h,每2周重复。结果近期有效率52.4%（11/21）,中位PFS时间12.7个月,1年生存率71.4%。主要毒副反应为骨髓抑制及外周神经毒性,发生率分别为66.9%、60.2%,多为Ⅰ~Ⅱ度。结论恩度隔日给药联合化疗治疗晚期消化道癌疗效好,不良反应可耐受。

Objective To evaluate efficacy and toxicity of endostatin administration every other day combined with first-line chemotherapy in the treatment of advanced gastrointestinal cancer. Methods A total of 21 patients with advanced gastrointestinal cancer received 7.5 mg/m2 endostatin every other day, 85 mg/m2d1 oxaliplatin, 200 mg/m2 IV d1 leucovorin, 400 mg/m2 IV d1 2,5-FU and 2.4 g/m2 CIV 2,5-FU for 46 hours, with a repetition every two weeks.Results The short term response rate（CR＋PR） was 52.3%（11/21）, and the median PFS time was 12.7 months with 71.4%one year survival rate. The main side effects were myelosuppression and peripheral neuropathy, and the incidence rates were 66.9% and 60.2% respectively, with most I-II degrees. Conclusion Endostatin administration every other day combined with first-line chemotherapy in the treatment of advanced gastrointestinal cancer has good efficacy, and it’s adverse reactions can be tolerated.